Patients.

Adverse event reporting and prescribing information can be found at the bottom of the page.

Are you a patient who has been prescribed an IBSA medicine?

No, I am not

Prescribed an IBSA medicine?

As a patient who has been prescribed an IBSA medicine, we understand that you may have some questions.

In this section, you will find all the information you need to support the use of your medication and your fertility journey going forward. Once you have selected the product that you have been prescribed, you will find a short video explaining how to prepare, inject and dispose of your treatment.

You will also find a patient pathway which identifies how each medication relates to the different stages of your fertility journey.

  • Fostimon (Urofollitropin)

    • Fostimon is used to promote ovulation in women who are not ovulating and who have not responded to other treatment (clomifene citrate)
    • It is used to bring about the development of several follicles (and therefore several eggs) in women receiving fertility treatment
    Two Fostimon product packs, showing 75 IU and 150 IU on a light background

  • Lubion (Progesterone)

    • Lubion is for women who need extra progesterone while undergoing treatment in an Assisted Reproductive Technology (ART) programme who are unable to use or tolerate vaginal preparations
    The Lubion 25mg product pack on a light background

  • Meriofert (Menotrophin)

    • Meriofert is used to promote ovulation in women who are not ovulating and who have not responded to other treatment (clomiphene citrate)
    • Meriofert is used to bring about the development of several follicles (and therefore several eggs) in women receiving fertility treatment
    Three Meriofert product packs, showing 75 IU, 150 IU and 900 IU, on a light background

  • Zivafert▼ (Human Chorionic Gonadatrophin)

    • To help develop and ripen several follicles (each containing an egg) in women undergoing assisted reproductive technologies (procedure that may help you to become pregnant) such as ‘in vitro fertilisation’ (IVF)
    • To help release an egg from the ovary (ovulation induction) in women who cannot produce eggs (‘anovulation’), or women who produce too few eggs (‘oligo-ovulation’)
    The Zivafert 5000 IU product pack on a light background

Navigating your fertility journey.

Embarking on the journey of fertility treatment can be both an emotional and complex process.

Understanding each phase of the journey can provide clarity and support as you work towards achieving your dream of parenthood.

An illustration of people on journeys

If you get any side-effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side-effects directly via the Yellow Card Scheme at yellowcard.mhra.gov.uk.

By reporting side-effects, you can help provide more information on the safety of this medicine.

To report a side effect or product complaint to IBSA Pharma please contact IBSA Pharma Ltd on 01923 233466 and medicalinformation.uk@ibsagroup.com.

▼ This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get.

See Yellow Card | Making medicines and medical devices safer (mhra.gov.uk) for how to report side effects.